Astrazeneca Pharma gets permission for launching oral lung cancer drug
DSIJ Intelligence / 24 Jul 2017
On Friday, Astrazeneca Pharma India announced after market hours, that the company has received an order from Drug Controller General of India for launching Osimertinib Tablets 40 mg and 80 mg in India.
On Friday, Astrazeneca Pharma India announced after market hours, that the company has received an order from Drug Controller General of India for launching Osimertinib Tablets 40 mg and 80 mg in India.
The company’s drug is an oral anti-cancer drug for the management of lung cancer. It is specialised for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), whose disease has progressed on or after EGFR TKI therapy.
45 countries including US, EU, Japan, China and other Asian countries have approved this tablet.
At Rs 1,002.40, the stock was trading up by 3.83% on BSE at 0930. It opened at Rs 984. Its 52-week high and low stood at Rs 1,146 and Rs 905, respectively.